Low Uptake Expected for New Fall Covid Vaccines in the U.S. in 2023.
A new round of Covid vaccines is set to arrive in the U.S. this fall, but experts believe that many Americans may be hesitant to receive them. The reasons behind this potential low uptake include:
- Pandemic fatigue.
- The perception that Covid is no longer a significant threat.
- Confusion over personal risk levels.
To increase vaccination rates, public health officials and healthcare providers may need to convey a new and straightforward message: Covid vaccines will likely become a routine part of protecting one’s health.
Vaccine manufacturers Pfizer, Moderna, and Novavax are expected to deliver new single-strain Covid shots in September, targeting the omicron subvariant XBB.1.5, currently the most immune-evasive strain of the virus.
However, getting people to take these new shots could be an uphill battle, considering the sluggish uptake of the most recent vaccines that were rolled out.
Only about 17% of the U.S. population has received Pfizer and Moderna’s bivalent Covid vaccines since their approval last September, and rates for older adults and other age groups are also relatively low.
Pandemic fatigue and the belief that Covid is over are some of the factors that may hinder the uptake of new shots. Many Americans have grown weary of protective measures such as masking, testing, and vaccination due to the prolonged duration of the pandemic. To address this issue, experts emphasize the personal benefits of receiving an additional vaccine.
Confusion over personal Covid risks and benefits from getting another shot is another factor that could hamper uptake. Risk levels vary among individuals, and some may be unsure about the necessity of getting an additional vaccine. Different circumstances, such as recent vaccinations or previous Covid infections, can further complicate decision-making for potential recipients.
The confusion over eligibility and recommendations for the new shots may persist even after the Food and Drug Administration approves the images. Personalized circumstances may make it challenging for health officials and healthcare providers to communicate clearly about the updated vaccines this fall.
To increase vaccine uptake, experts suggest conveying a clear message that Covid shots will likely be a regular part of healthcare in the future.
The FDA and CDC aim to transition towards a flu shot-like model for Covid vaccines, where people will receive a single jab annually that targets the latest variant expected to circulate in the fall and winter. This approach aims to simplify the vaccination process and encourage more people to get vaccinated.
However, whether the U.S. will update and distribute new shots annually is still being determined. Some advisors to the FDA have expressed concerns about shifting to yearly Covid vaccines, as it is unclear if the virus follows a seasonal pattern like the flu.
The shift to the commercial market for vaccine distribution may not significantly impact vaccine uptake, especially for insured Americans. Private insurers and government programs such as Medicare and Medicaid must cover all shots recommended by the CDC, ensuring most insured individuals can continue to receive Covid shots for free.
Efforts like the Biden administration’s Bridge Access Program aim to provide free Covid vaccines to uninsured people through 2024. Still, how many uninsured individuals will benefit from these initiatives remains uncertain.
Overall, boosting vaccine uptake in the fall may require clear and straightforward communication about the importance of Covid vaccination as a routine part of protecting one’s health.
By emphasizing the personal benefits and potential integration of Covid shots into regular healthcare, public health officials and healthcare providers can work towards increasing vaccination rates and mitigating the impact of the pandemic.
